Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a failed clinical trial.

Updates this week to the Gemini app on Android and iPhone introduce a new app icon that adopts the four Google colors.

After 18 months of planning and collaboration, Lake Catholic High School is launching a rebranded identity that includes new academic and athletic logos and a refined school seal. According to a ...

The Newest LEGO Architecture Set Is the Castle That Inspired Disney's Iconic Logo The Neuschwanstein castle is now up for preorder.

Jenna Bush Hager got a bob haircut live on the "TODAY" show, inspired by "White Lotus" star Leslie Bibb's style.

The launch of BMY’s Cobenfy provides context for Neurocrine’s own M4 targeting agonist and highlights the competitive landscape in neuroscience therapeutics.

Bristol-Myers Squibb faces patent losses and growth headwinds despite pipeline gains, debt cuts, and dividends. Read why BMY stock is a hold.

Cobenfy targets muscarinic acetylcholine (ACh) receptors, helping to reduce psychotic symptoms while causing fewer movement-related and metabolic side effects. Acetylcholine is a neurotransmitter.

The company’s Cobenfy’s ADEPT-2 top-line data in Alzheimer’s Disease Psychosis is anticipated in 2025, possibly as early as the second half of that year. According to Cantor Fitzgerald, this ...

AbbVie's $8.7bn play for Cerevel looks like a poor bet as its lead schizophrenia drug flunks two phase 2 trials, but which rival stands to benefit?

Research suggests that a new type of antipsychotic, xanomeline and trospium chloride (Cobenfy), is associated with significant improvements in cognitive symptoms among people with schizophrenia.